A face photo ranked cancer mortality risk—should it guide treatment?
A peer-reviewed model separated higher- and lower-risk patients in two retrospective radiotherapy cohorts, but it has not shown that face-based scores improve clinical decisions or outcomes.
The short version
- What happened
- The direct survival model was trained on 34,389 US patient photographs, tested on 3,822 held-out patients and externally validated in 4,892 radiotherapy patients in the Netherlands.
- Who it affects
- Patients should not read a face-based risk score as a diagnosis, life-expectancy estimate or reason to accept or refuse treatment.
- What remains unproven
- All clinical analyses were retrospective and drawn from radiotherapy cohorts rather than a prospective treatment study.
Keep in mind
All clinical analyses were retrospective and drawn from radiotherapy cohorts rather than a prospective treatment study.
The US test cohort was predominantly White, and transfer to under-represented groups, non-Western settings and non-cancer care remains uncertain.
The study measured discrimination and adjusted associations, not better decisions, fewer complications, improved survival or quality of life.
Residual confounding is possible because facial appearance may encode disease severity, treatment history, lifestyle and socioeconomic factors not fully captured by the adjustment set.
The survival-model weights and patient-level images are not publicly available for unrestricted independent reproduction.
Source analysis · 3 linked sources. Primary analysed source date: 19 October 2026.
Read the full report · 4 min The evidence, methods, implications and limitations
The model found a signal in two cancer cohorts
A single facial photograph contained information associated with survival among patients treated in radiotherapy services, according to a peer-reviewed model-development study published on 19 October. The researchers first trained a foundation model on more than 40 million face images. They then built one model to estimate facial age and another—FAHR-FaceSurvival—to rank mortality risk directly.
FAHR-FaceSurvival used 34,389 photographs from a US radiotherapy cohort for training and 3,822 held-out patients for testing. In that test set, its overall concordance index was 0.72, meaning it usually—but far from perfectly—ranked a patient who died sooner above one who survived longer. The highest-risk quartile had more than three times the adjusted mortality hazard of the lowest. The association persisted in a geographically separate cohort of 4,892 patients treated at Maastricht in the Netherlands.[1][2]
Useful risk information is not yet useful care
The study's scale and external cohort make it stronger than a single-centre proof of concept. The facial-age model was also tested on 38,211 US patients. Appearing at least five years older than chronological age was associated with a 21% higher adjusted mortality hazard; appearing at least five years younger was associated with a 17% lower hazard. In the Dutch cohort, both the facial-age deviation and direct survival score retained associations after adjustment for age, sex and cancer site.
Those are prognostic associations, not evidence that a face score improves treatment. Every clinical analysis was retrospective, and all patients came from radiotherapy records. The model was not compared prospectively with clinician judgement, a geriatric assessment, grip strength or a Timed Up and Go test. No study used the score to choose treatment, and no patient outcome, quality-of-life measure, waiting time or inequity measure was improved.[1]
The distinction that matters
What the study established—and what it did not
The evidence moves through three different steps that should not be collapsed into one claim.
Retrospective signal
Analyse stored face photographs and survival records
Mortality-risk ranking in two radiotherapy cohorts
Clinical comparison
Compare with clinicians and established frailty tools
Not prospectively tested
Patient benefit
Use the score in real treatment decisions
No outcome trial reported
Bias, privacy and reproducibility remain live questions
The US test cohort was 87.6% White. Performance varied across demographic and cancer subgroups, and the association for Hispanic patients was not statistically conclusive, with a very wide confidence interval. The authors say common changes in pose, light, expression and makeup did not materially alter facial-age estimates, but cancer-only cohorts from mainly Western centres limit transfer to other diseases, health systems and populations.
The study was funded by the European Research Council, with the funder reported to have no role in the work. Several authors disclosed industry relationships, and Mass General Brigham has filed a provisional US patent covering next-generation facial-health algorithms. Code and the age-model weights are public, but the survival-model weights and patient photographs are not. Before clinical use, independent prospective studies would need consent and privacy safeguards, prespecified comparators, subgroup performance, calibration and evidence that decisions and patient outcomes improve.[1][2][3]